PARK7 and ovarian carcinoma: Moreover, DJ-1 is upregulated and correlated with patient prognosis in various types of cancer, including NSCLC 43, ovarian carcinoma 44, and CRC 23, indicating that DJ-1 acts as an oncogene and can be a potential therapeutic target for cancer treatment 17.